Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Day One Biopharmaceuticals, Inc.
Rain Oncology Inc
RECORDATI GROUP
Hoffmann-La Roche
Novartis
EMD Serono
University of California, San Francisco
Merck Sharp & Dohme LLC
INSYS Therapeutics Inc